acetylleucyl-leucyl-norleucinal has been researched along with Ataxia Telangiectasia Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piette, J; Piret, B; Schoonbroodt, S | 1 |
1 other study(ies) available for acetylleucyl-leucyl-norleucinal and Ataxia Telangiectasia Syndrome
| Article | Year |
|---|---|
The ATM protein is required for sustained activation of NF-kappaB following DNA damage.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cells, Cultured; Child; Child, Preschool; DNA Damage; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Inhibitors; Fibroblasts; Gene Expression Regulation; Glioblastoma; Humans; I-kappa B Proteins; Leupeptins; NF-kappa B; NF-KappaB Inhibitor alpha; Nuclear Proteins; Phosphoric Monoester Hydrolases; Protease Inhibitors; Protein Serine-Threonine Kinases; Proteins; Radiation Tolerance; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Transcription, Genetic; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 1999 |